Dr. Strohbehn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2215 Fuller Rd
Ann Arbor, MI 48105Phone+1 734-769-7100
Summary
- I am a hematology and oncology fellow and medical educator with interests in randomized trials in the theory and science of medical decision-making and high-value clinical practice and research. Using cognitive psychological and behavioral economics techniques, my goal is to conduct collaborative research exploring therapeutic decision-making and, in doing so, shape value-oriented policy and both graduate and undergraduate medical education at the national level. Additional interests include incorporation of the arts in medicine and trial design in medical education.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2018 - 2021
University of MichiganChief Residency, Internal Medicine, 2017 - 2018- University of MichiganResidency, Internal Medicine, 2014 - 2017
Yale School of MedicineClass of 2014, MD
University of IowaBS, BA, Biochemistry, Chemistry, Summa Cum Laude, 2004 - 2008
Certifications & Licensure
MI State Medical License 2017 - 2027
IL State Medical License 2018 - 2023- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Richard and Debra Gonzalez Research Fellow University of Chicago
- Future Leaders Award High Value Practice Academic Alliance, 2017-2018
- NIH Clinical and Translational Science Award Medical Student Grantee NIH Yale CTSA, 2011-2012
- Join now to see all
Clinical Trials
- Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19 Start of enrollment: 2020 Sep 10
Publications & Presentations
PubMed
- 1 citationsEffectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study.Sean Miller, Ralph Jiang, Matthew Schipper, Lars G Fritsche, Garth Strohbehn
The Lancet. Oncology. 2024-12-01 - Pan-Cancer Survival Impact of Immune Checkpoint Inhibitors in a National Healthcare System.Sean R Miller, Matthew Schipper, Lars G Fritsche, Ralph Jiang, Garth Strohbehn
Cancer Medicine. 2024-11-01 - The tyranny of non-inferiority trials.Ian F Tannock, Marc Buyse, Mickael De Backer, Helena Earl, Daniel A Goldstein
The Lancet. Oncology. 2024-10-01
Journal Articles
- Precision and Accuracy in the Brave New World of Basket TrialsStrohbehn GW, Ratain MJ, JCO Precision Oncology, 6/19/2019
- Transforming Chief Residents Into Chief ScholarsStrohbehn GW, Tapper EB, and Del Valle J, Medical Science Educator, 7/30/2019
Other
- Assessing the true cost of cancer care: Measuring and mitigating financial toxicity.Strohbehn GW, Bestvina CM
https://dailynews.ascopubs.org/do/10.1200/ADN.19.190397/full/
Invited Expert Editorial - ASCO Daily News - 9/5/2019
Authored Content
- Sotorasib, the Poster Child for Project Optimus: Truths and FantasiesFebruary 2024
Press Mentions
Optimizing Cancer Treatment Delivery Could Cut down Greenhouse Gas Emissions and Save LivesJuly 26th, 2024- Despite Benefits, Extended-Interval Pembro Uptake Remains LowSeptember 28th, 2022
- Despite Benefits, Extended-Interval Pembro Uptake Remains LowSeptember 27th, 2022
- Join now to see all
Professional Memberships
- Member
- Member
- International Association for the Study of Lung Cancer (IASLC)Member
- Member
- High Value Practice Academic AllianceMember
External Links
- Google Scholarhttps://scholar.google.com/citations?user=Cw_5tVsAAAAJ&hl=en&oi=ao
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
